Anuh Pharma Limited (ANUHPHR) — Announcement | 28 May 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Anuh Pharma Limited announced its Q4 FY2025-26 investor presentation, highlighting 15.66% YoY revenue growth to Rs. 776 crores driven by volume expansion and regulated market penetration, alongside successful USFDA and EU GMP inspections. The presentation underscores strategic capacity enhancements, geographic diversification to mitigate currency risk, and confidence in 15-20% annual growth, supported by strong export contributions (46% of revenue) and robust compliance credentials.

📄 View Original Announcement (PDF)

About Anuh Pharma Limited (ANUHPHR)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹896.2 Cr P/E: 20.3 ROE: 12.5% ROCE: 17.2% Div Yield: 1.68%

View full ANUHPHR stock details →

📡 Get AI alerts when ANUHPHR files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ANUHPHR — Free

📊 More ANUHPHR filings

See all ANUHPHR filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ANUHPHR files new disclosures

Track ANUHPHR filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ANUHPHR — Free

Free account · 2 AI queries/day